We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00557336
First Posted: November 14, 2007
Last Update Posted: February 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
  Purpose
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the height gain during 12 months of growth hormone treatment in children born small for gestational age due to intrauterine growth retardation.

Condition Intervention Phase
Foetal Growth Problem Small for Gestational Age Drug: somatropin Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy and Safety of Somatropin in SGA Children Due to IUGR

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Height gain according to birth group, age of onset, the treatment and Tanner stage [ Time Frame: during 12 months of treatment ]

Secondary Outcome Measures:
  • Height SDS for bone age [ Time Frame: during 12 months of treatment ]
  • Height velocity SDS for bone age [ Time Frame: during 12 months of treatment ]
  • Height velocity for chronological age [ Time Frame: during 12 months of treatment ]

Enrollment: 160
Actual Study Start Date: July 28, 2003
Study Completion Date: June 29, 2005
Primary Completion Date: June 29, 2005 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Born small for gestational age (SGA) due to intrauterine growth retardation (IUGR) defined as birth length and/or weight below P10
  • Chronological age at least 4 years old until bone age maturation of maximum 12 years for girls and maximum 13,5 for boys at time of inclusion in the study
  • Insufficient catch-up growth (height lesser than or equal to -2.5 SDS for chronological age
  • Normal response to GH stimulation test (greater than 10 ng/mL)

Exclusion Criteria:

  • Diabetes
  • Growth retardation associated with infections severe chronic diseases (including chromosomal anomaly or nutritional disorders)
  • Treatment with any medical product (anabolic drugs, sex steroids, etc.) which may interfere with GH effects
  • History or presence of severe disease that could interfere with GH treatment/participation in the trial, e.g. active malignancy
  • Previous or ongoing growth hormone therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00557336


Locations
Spain
Novo Nordisk Investigational Site
Albacete, Spain, 02006
Novo Nordisk Investigational Site
Alicante, Spain, 03010
Novo Nordisk Investigational Site
Almería, Spain, 04009
Novo Nordisk Investigational Site
Badajoz, Spain, 06080
Novo Nordisk Investigational Site
Badalona, Spain, 08916
Novo Nordisk Investigational Site
Barcelona, Spain, 08009
Novo Nordisk Investigational Site
Barcelona, Spain, 08025
Novo Nordisk Investigational Site
Calella de la Costa, Spain, 08370
Novo Nordisk Investigational Site
Cáceres, Spain, 10002
Novo Nordisk Investigational Site
Córdoba, Spain, 14004
Novo Nordisk Investigational Site
El Palmar, Spain, 30120
Novo Nordisk Investigational Site
Elche, Spain, 3203
Novo Nordisk Investigational Site
Esplugues Llobregat, Spain, 08950
Novo Nordisk Investigational Site
Getafe, Spain, 28905
Novo Nordisk Investigational Site
Granada, Spain, 18012
Novo Nordisk Investigational Site
Granollers, Spain, 08400
Novo Nordisk Investigational Site
Huelva, Spain, 21005
Novo Nordisk Investigational Site
Jaén, Spain, 23007
Novo Nordisk Investigational Site
Las Palmas, Spain, 35016
Novo Nordisk Investigational Site
Leganés, Spain, 28911
Novo Nordisk Investigational Site
Madrid, Spain, 28007
Novo Nordisk Investigational Site
Madrid, Spain, 28009
Novo Nordisk Investigational Site
Madrid, Spain, 28041
Novo Nordisk Investigational Site
Madrid, Spain, 28046
Novo Nordisk Investigational Site
Martorell, Spain, 08760
Novo Nordisk Investigational Site
Mataró, Spain, 08304
Novo Nordisk Investigational Site
Málaga, Spain, 29011
Novo Nordisk Investigational Site
Palma de Mallorca, Spain, 07014
Novo Nordisk Investigational Site
Pamplona, Spain, 31008
Novo Nordisk Investigational Site
Sabadell, Spain, 08208
Novo Nordisk Investigational Site
Salamanca, Spain, 37007
Novo Nordisk Investigational Site
Santa Cruz de Tenerife, Spain, 38010
Novo Nordisk Investigational Site
Santander, Spain, 39008
Novo Nordisk Investigational Site
Sevilla, Spain, 41014
Novo Nordisk Investigational Site
Tarrasa, Spain, 08227
Novo Nordisk Investigational Site
Vitoria, Spain, 01009
Novo Nordisk Investigational Site
Zaragoza, Spain, 50009
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00557336     History of Changes
Other Study ID Numbers: GHLIQUID-1523
First Submitted: November 12, 2007
First Posted: November 14, 2007
Last Update Posted: February 28, 2017
Last Verified: February 2017